Saturday 17 October 2026
Export GH’s income statement to Excel — free account
Guardant Health, Inc.
GH Healthcare Diagnostics & Research
Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024. In the quarter to June 2026, revenue grew 44.3%, EPS fell 12.5%, free cash flow fell 5.46% and total debt rose 34.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
158.29
7.59
−4.58%
Follow GH
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 5 | 5 | 5 |
| 192.39% | 348.42% | 200.62% | 171.64% | ||
| (28.33%) | (23.79%) | (26.58%) | (27.95%) | ||
ROIC |
(153.52%) | (134.56%) | (127.36%) | (129.70%) | |
Return on Tangible Assets |
(55.65%) | (31.80%) | (35.35%) | (38.40%) | |
Average Days of Receivables |
46.74 | 51.24 | 46.43 | 44.50 | |
Free Cash Flow per Share |
(2.10) | (1.86) | (1.81) | (1.81) | |
Free Cash Flow |
(262.23) | (233.07) | (237.12) | (240.72) | |
Capital Expenditures |
(39.33) | (48.31) | (49.43) | (55.54) | |
| Other line items | |||||
Cash ROIC |
(19.57%) | (8.94%) | (9.78%) | (10.32%) | |
Accounts Receivable Turnover |
8.85 | 7.92 | 8.55 | 8.62 | |
Accounts Payable Turnover |
18.37 | 7.51 | 6.08 | 5.99 | |
Inventory Turnover |
4.02 | 4.45 | 4.71 | 4.37 | |
Average Days of Payables |
22.48 | 56.94 | 72.22 | 82.46 | |
Days of Inventory on Hand |
100.97 | 89.81 | 80.71 | 92.99 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
39.83% | 37.09% | 33.95% | 31.76% | |
Selling, General and Administrative Expense of Revenue |
72.95% | 71.90% | 72.38% | 73.00% | |
Share Based Compensation of Revenue |
17.66% | 16.93% | 16.30% | 16.17% | |
Interest Coverage |
(131.59) | (112.20) | (100.51) | (97.65) | |
Operating CF/Net income |
0.56 | 0.44 | 0.43 | 0.41 | |
Depreciation/Fixed assets |
0.27 | 0.23 | 0.18 | 0.16 | |
Capex/Depreciation |
(1.18) | (1.43) | (1.84) | (2.19) | |
Revenue per Share |
7.23 | 7.83 | 8.23 | 8.90 | |
Operating CF per Share |
(1.79) | (1.47) | (1.43) | (1.39) | |
Capex per Share |
(0.32) | (0.39) | (0.38) | (0.42) | |
Capex to Sales |
0.04 | 0.05 | 0.05 | 0.05 |
Columns are period end dates